Impact of prolonged dose delays on response with belantamab mafodotin (belamaf; gsk2857916) treatment in dreamm-2 study: 13-month follow-up
Introduction: Single-agent belamaf (BLENREP) demonstrated deep and durable responses in the DREAMM-2 (NCT03525678) primary analysis(1) and long-term follow-up.(2,3) Keratopathy (microcyst-like epithelial changes [MECs] observed on eye examination with/without symptoms) were managed through dose del...
Main Authors: | , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
PAGEPress Publications
2020-09-01
|
Series: | Hematology Reports |
Online Access: | https://www.pagepress.org/journals/index.php/hr/article/view/8918 |